Form 4: United Therapeutics CFO Exercises Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO and Treasurer of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of common stock on September 3, 2024.
• The transactions were made pursuant to a Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised stock options at prices of $120.26 and $117.76.
• He sold shares at a price of $362.37.
• Some option exercises were 'sell-to-cover' transactions, where a portion of the shares obtained from exercising options were sold to cover the exercise cost.
• Following these transactions, Edgemond directly owns 3,162 shares of common stock.
• Edgemond also holds 37,570 and 36,754 stock options exercisable at $120.26, and 150,600 and 149,750 stock options exercisable at $117.76.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. The CFO still holds a significant number of options.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
• Edgemond continues to hold a significant number of stock options, indicating a continued alignment with the company's long-term success.

Negatives

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Risks

• While the Rule 10b5-1 plan provides a framework, significant and consistent selling by insiders could still negatively impact investor sentiment.

Industry Context

Executive compensation and trading activity are closely watched in the pharmaceutical industry. Rule 10b5-1 plans are a common tool for executives to manage their stock holdings while avoiding accusations of insider trading.

Comparison to Industry Standards

• Many pharmaceutical companies use stock options as part of their executive compensation packages.
• The use of Rule 10b5-1 trading plans is a standard practice among executives in publicly traded companies to manage their stock transactions.
• Comparing the size of Edgemond's stock option grants and share sales to those of CFOs at similarly sized pharmaceutical companies could provide further context.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on their interpretation of insider selling activity.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates